The Solventum Corporation (NYSE: SOLV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents help investors, analysts and other stakeholders understand Solventum’s financial performance, portfolio actions, capital structure and governance as it operates in the medical instruments and supplies sector.
Solventum uses current reports on Form 8-K to disclose a variety of material events. Examples include 8-K filings reporting quarterly financial results, such as third-quarter 2025 earnings, which incorporate press releases detailing segment performance, non-GAAP measures and updated guidance. Other 8-K filings describe material definitive agreements and their completion, such as the transaction agreement and subsequent closing of the sale of certain assets and liabilities related to Solventum’s purification and filtration business to Thermo Fisher Scientific Inc.
Additional 8-K filings cover capital markets and balance sheet activities, including the commencement, upsizing and pricing of cash tender offers for specified series of senior notes, and an underwriting agreement relating to the sale of shares by a selling shareholder. Governance and leadership changes, such as the appointment of a Chief Commercial Officer and the departure of a segment leader, are also reported on Form 8-K, along with information about related compensation and severance arrangements.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key points in clear language. This includes highlighting where Solventum discusses its “Transform for the Future” initiative, outlines risk factors, or provides pro forma financial information related to divestitures. The filings page is also a resource for tracking Solventum’s capital allocation strategy, including debt reduction, note tender offers and the authorization of a share repurchase program, as disclosed in its official documents.
Independent Franchise Partners, LLP filed an amended Schedule 13G reporting its beneficial ownership of common stock of CORPORATION. The firm reports beneficial ownership of 15,355,691 shares, representing 8.85% of the outstanding common stock as of the event date. It has sole voting power over 15,002,913 shares and shared voting power over 91,652 shares. It also has sole dispositive power over all 15,355,691 shares and no shared dispositive power. The filer states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Solventum Corp reported an insider equity transaction by its Chief Human Resources Officer, Tammy L. Gomez. On 01/02/2026, she acquired 4,342 shares of Solventum common stock through the settlement of restricted stock units. On the same date, 1,332 shares were disposed of at $79.2 per share, typically reflecting shares withheld to cover taxes.
After these transactions, Gomez directly beneficially owned 8,665 shares of Solventum common stock. The filing explains that each RSU converts into one share of common stock upon settlement, and that the RSUs vest in three equal annual tranches on the first, second, and third anniversaries of the grant date, subject to continued service.
Solventum Corporation furnished a letter to its shareholders under a Regulation FD disclosure.
On December 16, 2025, the company issued a shareholder letter and attached it as Exhibit 99.1 to a current report. The company states that this information is being furnished, not filed, so it is not subject to liability under Section 18 of the Exchange Act and will only be incorporated into other securities filings if specifically referenced. Solventum’s common stock, with a par value of $0.01 per share, trades on the New York Stock Exchange under the symbol SOLV.
Solventum Corp’s Chief Legal Affairs Officer reported routine equity transactions in company stock. On 12/01/2025, the officer exercised 3,811 restricted stock units, receiving the same number of Solventum common shares as they fully vested. To cover tax obligations, 1,510 shares were disposed of at a price of $85.56 per share. After these transactions, the officer directly owned 8,056 shares of Solventum common stock. These transactions were reported on a Form 4 as a single‑person filing.
Solventum Corp reported an insider equity transaction by its Chief Supply Chain Officer, who filed individually. On 12/01/2025, 10,463 shares of common stock were acquired through the settlement of fully vested restricted stock units, reflected as a Code M transaction. On the same date, 4,528 shares of common stock were disposed of in a Code F transaction at $85.56 per share, typically indicating shares withheld to cover taxes.
After these transactions, the officer beneficially owned 15,943 shares of Solventum common stock in direct ownership. All related restricted stock units were fully vested, and each RSU represented the right to receive one share of common stock upon settlement.
Solventum Corp (SOLV) reported an equity award to its Chief Commercial Officer in a Form 4 insider transaction filing. The officer received 78,751 restricted stock units (RSUs) on November 17, 2025. Each RSU represents the right to receive one share of Solventum Class A common stock upon settlement.
The RSUs vest in three equal tranches, with one-third vesting on November 17, 2026, one-third on November 17, 2027, and the final third on November 17, 2028, assuming continued service through each vesting date. Following this grant, the filing shows 78,751 derivative securities beneficially owned on a direct basis, reflecting this new RSU award as part of the executive's long‑term incentive compensation.
Solventum Corp (SOLV) filed an initial ownership report for one of its officers. The reporting person serves as Chief Commercial Officer of Solventum Corp and submitted a Form 3 as an initial statement of beneficial ownership as of 11/10/2025. The filing states that no securities are beneficially owned by this officer at the time of the reported event, and that a power of attorney (Exhibit 24.1) authorizes the attorney-in-fact to sign on the officer’s behalf.
Independent Franchise Partners, LLP filed an amended Schedule 13G (Amendment No. 1) reporting beneficial ownership of 12,899,240 shares of Solventum Corporation common stock, representing 7.44% of the class as of 09/30/2025.
The filer reports 12,626,471 shares with sole voting power and 77,036 with shared voting power. It has 12,899,240 shares with sole dispositive power and 0 with shared dispositive power. The filing certifies the securities were acquired and are held in the ordinary course of business and not with the purpose or effect of changing or influencing control of the issuer.
Solventum Corporation (SOLV) reported Q3 2025 results highlighted by a completed divestiture and significant de-leveraging. The company sold its Purification and Filtration business to Thermo Fisher for approximately $4 billion cash, recording a pre-tax gain of approximately $1.5 billion (net of $86 million in transaction fees). Q3 diluted EPS was $7.22 on total net sales of $2,096 million.
Long-term debt declined to $5,137 million from $7,810 million at year-end, aided by cash tender offers retiring $1.9 billion of senior notes, which produced an $82 million loss on extinguishment (including instruments activity). Cash and equivalents rose to $1,642 million. Operating cash flow for the nine months was $274 million, reflecting the non-cash nature of the $1,518 million gain and working capital movements. The company recognized an unfavorable contract liability of $113 million tied to transition services and recorded a $64 million liability related to a potential payment of up to $75 million associated with the excluded Water Business.
Q3 gross profit was $1,135 million; SG&A was $780 million and R&D was $183 million. Shares outstanding were 173,439,525 as of September 30, 2025.
Solventum Corporation furnished an update on its business by reporting third‑quarter 2025 results and providing the related press release as Exhibit 99.1 under Item 2.02 of a Form 8‑K. The exhibit contains the detailed financial results and commentary. The filing notes the press release is furnished, not filed, under the Exchange Act.